Search

Your search keyword '"Thomas-Schoemann, A."' showing total 13 results
Start Over Author "Thomas-Schoemann, A." Language french
13 results on '"Thomas-Schoemann, A."'

5. Les auteurs

Author

Aulagner, Gilles, Cazin, Jean-Louis, Lemare, François, Limat, Samuel, Armoiry, Xavier, Astier, Alain, Barbier, Garance, Bardin, Christophe, Boiteux-Jurain, Marie, Boulin, Mathieu, Brunie, Vanida, Burtin, Christophe, Capelle, Aude, Chaigneau, Loïc, Chenailler, Catherine, Chinot, Olivier, Clairet, Anne-Laure, Correard, Florian, Daguindau, Étienne, Dahan, Muriel, Dansin, Éric, Debordeaux, Frédéric, Demoré, Béatrice, Desmaris, Romain, Dussart, Claude, Estève, Marie-Anne, Fagnoni, Philippe, Faucitano, Alexia, Faure, Pierre, Favé, Sophie, Fernandez, Christine, Gaillard, Claire, Goldwasser, François, Govindoorazoo, Axel, Gueneau, Pauline, Guerrini-Rousseau, Léa, Guyotat, Denis, Henaine, Anne-Marie, Honoré, Stéphane, Jary, Marine, Jeannin, Marie, Jonchere, Gabrielle, Kalbacher, Elsa, Kroemer, Marie, Kuzzay, Marie-Pierre, Levêque, Dominique, Madelaine, Isabelle, Mansi, Laura, Mimoun, Aguirre, Mongaret, Céline, Nerich, Virginie, Noirez, Véronique, Penel, Nicolas, Piketty, Anne-Catherine, Pistre, Pauline, Puisset, Florent, Rizzo-Padoin, Nathalie, Roy, Pétronille, Sautou, Valérie, Servent, Véronique, Slimano, Florian, Spiesser-Robelet, Laurence, Thiery-Vuillemin, Antoine, Thomas-Schoemann, Audrey, Tournamille, Jean-François, Valteau-Couanet, Dominique, Vienot, Angélique, Vigneron, Jean, Villeminey, Clémentine, Vinson, Camille, Braguer, Diane, Chaigneau, Aurélie, Chaussard, Michaël, Demirdjian, Sylvie, Gaudin, Amélie, Guénée de Courtivron, Charlotte, Hosten, Benoît, Morel, Daphné, Opsomer, Marie-Agnès, Petit, Marie, and Pinel, Sylvine

Published
2020
Full Text
View/download PDF

6. [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]

Author

Marie, Bretagne, Pascaline, Boudou-Rouquette, Olivier, Huillard, Audrey, Thomas-Schoemann, Anne, Chahwakilian, Galdric, Orvoen, Jennifer, Arrondeau, Camille, Tlemsani, Anatole, Cessot, Laure, Cabanes, Benoit, Blanchet, Romain, Coriat, Jérôme, Alexandre, and François, Goldwasser

Subjects
Aged, 80 and over, Niacinamide, Indazoles, Indoles, Axitinib, Neovascularization, Pathologic, Pyridines, Phenylurea Compounds, Imidazoles, Angiogenesis Inhibitors, Sorafenib, Kidney, Receptors, Vascular Endothelial Growth Factor, Piperidines, Quinazolines, Sunitinib, Humans, Pyrroles, Protein Kinase Inhibitors, Fatigue, Aged
Abstract

Angiogenesis inhibition is a major antitumor strategy that has emerged during the last decade. Oral tyrosine kinase inhibitors (TKI) targeting the VEGF receptor, including sunitinib, sorafenib, axitinib, regorafenib, pazopanib, and vandetanib reduce tumor growth and metastasis. These agents are approved for the treatment of metastatic diseases in first or second-line. They display a narrow therapeutic index. However, data in the elderly and/or in patients with multiple illnesses remain scarce. This population is classically excluded from clinical trials. The aim of this review is to provide an overview of existing literature regarding antiangiogenic TKI tolerance in the elderly (70 years old). We also highlight key points of the pre-therapeutic evaluation and summarize the management of common toxicities.

Published
2015

8. [Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study]

Author

Audrey, Thomas-Schoemann, Jérôme, Alexandre, Céline, Mongaret, Sonia, Azibi, Alain, Dauphin, François, Goldwasser, and Francois, Lemare

Subjects
Complementary Therapies, Male, Tea, Acupuncture Therapy, Antineoplastic Agents, Homeopathy, Vitamins, Middle Aged, Relaxation Therapy, Antioxidants, Beverages, Neoplasms, Humans, Drug Interactions, Female, France, Prospective Studies, Selenium Compounds, Hypnosis, Aged, Phytotherapy
Abstract

Use of complementary and alternative medicine (CAM) has been reported to be more and more frequent among cancer patients in USA. The aim of this study was to analyze among French cancer patients the prevalence of CAM use, focusing on antioxidants (AO) that could interfere with antitumor agents. Seventy-nine patients, treated by antitumor chemotherapy in oncology day care unit, participated to an interview (medium age = 60 years old). CAM use was reported by 42% of patients: mostly AO (24%) (selenium, green tea and vitamins ACE, more specifically), but also relaxation, acupuncture, hypnosis (19%) and homeopathy (15%). Among patients using CAM, 66% of them indicated that their physicians were not aware of this use and 47% of them thought that CAM use was safe. Nevertheless, for seven patients who have taken AO, previous in vitro and preclinical studies suggested interactions with antitumor chemotherapy. Therefore, CAM use and, more specifically, AO use is common among cancer patients treated by antitumor chemotherapy in France. Nevertheless, AO could generate interactions with conventional treatment. Clinical studies are warranted to evaluate these interactions, and adequate communication with patients is needed.

Published
2011

9. Liste des collaborateurs

Author

Armoiry, Xavier, Astier, Alain, Aulagner, Gilles, Bardin, Christophe, Bichard, Damien, Boulin, Mathieu, Braguer, Diane, Breilh, Dominique, Brunie, Vanida, Burtin, Christophe, Cazin, Jean-Louis, Chaigneau, Aurélie, Chaussard, Michaël, Chenailler, Catherine, Chinot, Olivier, de Courtivron, Charlotte, Dahan, Muriel, Dansin, Éric, Demirdjian, Sylvie, Demoré, Béatrice, Desmaris, Romain-Pacôme, Estève, Marie-Anne, Fagnoni, Philippe, Faure, Pierre, Fernandez, Christine, Gaudin, Amélie, Guerrini-Rousseau, Léa, Goldwasser, François, Honoré, Stéphane, Hosten, Benoît, Kalbacher, Elsa, Kuzzay, Marie-Pierre, Latour, Jean-François, Lemare, François, Lévêque, Dominique, Limat, Samuel, Madelaine, Isabelle, Mateus, Christine, Mimoun, Aguirre, Mongaret, Céline, Morel, Daphné, Nerich, Virginie, Noé, Gaëlle, Noirez, Véronique, Opsomer, Marie-Agnès, Penel, Nicolas, Petit, Marie, Pinel, Sylvine, Puisset, Florent, Rizzo-Padoin, Nathalie, Robert, Caroline, Sautou, Valérie, Servant, Vincent, Servent, Véronique, Spiesser-Robelet, Laurence, Thiery-Vuillemin, Antoine, Thomas-Schoemann, Audrey, Tournamille, Jean-François, Valteau-Couanet, Dominique, Vigneron, Jean, Voidey, Aline, and Xuereb, Fabien

Published
2016
Full Text
View/download PDF

11. [Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].

Author

Zaibet S, Vauchier C, Khoudour N, Roulleaux Dugage M, Korb-Savoldelli V, Alexandre J, Blanchet B, Goldwasser F, Thomas-Schoemann A, and Bellesoeur A

Subjects
Administration, Oral, Antineoplastic Agents adverse effects, Drug Interactions, Humans, Hypertension chemically induced, Molecular Targeted Therapy methods, Precision Medicine trends, Protein Kinase Inhibitors therapeutic use, Antineoplastic Agents administration & dosage, Neoplasms drug therapy, Precision Medicine methods
Abstract

Oral targeted therapies are a growing class of medication. After clinical trials conducted on a selected population, these molecules are usually approved at a fixed dose. However, oral tyrosine kinase inhibitors are characterized by a large intra and inter-individual pharmacokinetic variability, and a narrow therapeutic index. Hence, their prescription is hazardous and unsafe in non-selected people from daily clinical practice. The increasing number of available targeted therapies point out new challenges. These challenges should especially concern prescription for out of the ordinary patients, rules for dose adjustment according to factors of frailty. The ultimate goal is to ensure a safe and individualized prescription. Moreover, many of these molecules are metabolized by the CYP3A4, leading to a serious risk of drug interaction. These interactions might involve not only conventional medicine but also alternative and complementary medicines. These latter are more and more common but oncologists often lack experience about them. Finally, the oral route raises the issues of adherence, and the question of its assessment should now become a permanent part of patients care., (Copyright © 2018.)

Published
2018
Full Text
View/download PDF

12. [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].

Author

Bretagne M, Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J, Tlemsani C, Cessot A, Cabanes L, Blanchet B, Coriat R, Alexandre J, and Goldwasser F

Subjects
Aged, Aged, 80 and over, Axitinib, Fatigue chemically induced, Humans, Imidazoles adverse effects, Indazoles adverse effects, Indoles adverse effects, Kidney drug effects, Niacinamide adverse effects, Niacinamide analogs & derivatives, Phenylurea Compounds adverse effects, Piperidines adverse effects, Pyridines adverse effects, Pyrroles adverse effects, Quinazolines adverse effects, Sorafenib, Sunitinib, Angiogenesis Inhibitors adverse effects, Neovascularization, Pathologic drug therapy, Protein Kinase Inhibitors adverse effects, Receptors, Vascular Endothelial Growth Factor antagonists & inhibitors
Abstract

Angiogenesis inhibition is a major antitumor strategy that has emerged during the last decade. Oral tyrosine kinase inhibitors (TKI) targeting the VEGF receptor, including sunitinib, sorafenib, axitinib, regorafenib, pazopanib, and vandetanib reduce tumor growth and metastasis. These agents are approved for the treatment of metastatic diseases in first or second-line. They display a narrow therapeutic index. However, data in the elderly and/or in patients with multiple illnesses remain scarce. This population is classically excluded from clinical trials. The aim of this review is to provide an overview of existing literature regarding antiangiogenic TKI tolerance in the elderly (>70 years old). We also highlight key points of the pre-therapeutic evaluation and summarize the management of common toxicities., (Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2016
Full Text
View/download PDF

13. [Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study].

Author

Thomas-Schoemann A, Alexandre J, Mongaret C, Azibi S, Dauphin A, Goldwasser F, and Lemare F

Subjects
Acupuncture Therapy statistics & numerical data, Aged, Beverages, Drug Interactions, Female, France, Homeopathy statistics & numerical data, Humans, Hypnosis statistics & numerical data, Male, Middle Aged, Phytotherapy statistics & numerical data, Prospective Studies, Relaxation Therapy statistics & numerical data, Selenium Compounds therapeutic use, Tea, Vitamins therapeutic use, Antineoplastic Agents therapeutic use, Antioxidants therapeutic use, Complementary Therapies statistics & numerical data, Neoplasms drug therapy
Abstract

Use of complementary and alternative medicine (CAM) has been reported to be more and more frequent among cancer patients in USA. The aim of this study was to analyze among French cancer patients the prevalence of CAM use, focusing on antioxidants (AO) that could interfere with antitumor agents. Seventy-nine patients, treated by antitumor chemotherapy in oncology day care unit, participated to an interview (medium age  =  60 years old). CAM use was reported by 42% of patients: mostly AO (24%) (selenium, green tea and vitamins ACE, more specifically), but also relaxation, acupuncture, hypnosis (19%) and homeopathy (15%). Among patients using CAM, 66% of them indicated that their physicians were not aware of this use and 47% of them thought that CAM use was safe. Nevertheless, for seven patients who have taken AO, previous in vitro and preclinical studies suggested interactions with antitumor chemotherapy. Therefore, CAM use and, more specifically, AO use is common among cancer patients treated by antitumor chemotherapy in France. Nevertheless, AO could generate interactions with conventional treatment. Clinical studies are warranted to evaluate these interactions, and adequate communication with patients is needed.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results